Literature DB >> 8593028

Activity of lipopolysaccharide-binding protein-bactericidal/permeability-increasing protein fusion peptide in an experimental model of Pseudomonas sepsis.

S M Opal1, J E Palardy, J W Jhung, C Donsky, R L Romulo, N Parejo, M N Marra.   

Abstract

A chimeric protein consisting of the N-terminal domain of lipopolysaccharide-binding protein and the C-terminal domain of bactericidal/permeability-increasing protein demonstrated a dose-dependent survival benefit (P = 0.001) and reduced endotoxin levels (P < 0.01) in neutropenic rats with Pseudomonas aeruginosa sepsis. This lipopolysaccharide-binding protein-bactericidal/ permeability-increasing peptide has favorable pharmacokinetics and antiendotoxin properties which may be of value for human sepsis.

Entities:  

Mesh：

Substances：

Year:  1995        PMID： 8593028      PMCID： PMC163038          DOI： 10.1128/AAC.39.12.2813

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  24 in total

1.  Purification and characterization of a potent bactericidal and membrane active protein from the granules of human polymorphonuclear leukocytes.

Authors:  J Weiss; P Elsbach; I Olsson; H Odeberg
Journal:  J Biol Chem       Date:  1978-04-25       Impact factor: 5.157

2.  Structure and function of lipopolysaccharide binding protein.

Authors:  R R Schumann; S R Leong; G W Flaggs; P W Gray; S D Wright; J C Mathison; P S Tobias; R J Ulevitch
Journal:  Science       Date:  1990-09-21       Impact factor: 47.728

3.  Efficacy of a monoclonal antibody directed against tumor necrosis factor in protecting neutropenic rats from lethal infection with Pseudomonas aeruginosa.

Authors:  S M Opal; A S Cross; N M Kelly; J C Sadoff; M W Bodmer; J E Palardy; G H Victor
Journal:  J Infect Dis       Date:  1990-06       Impact factor: 5.226

4.  Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from a randomized, double-blind, placebo-controlled trial. Phase III rhIL-1ra Sepsis Syndrome Study Group.

Authors:  C J Fisher; J F Dhainaut; S M Opal; J P Pribble; R A Balk; G J Slotman; T J Iberti; E C Rackow; M J Shapiro; R L Greenman
Journal:  JAMA       Date:  1994-06-15       Impact factor: 56.272

5.  Bactericidal/permeability-increasing protein has endotoxin-neutralizing activity.

Authors:  M N Marra; C G Wilde; J E Griffith; J L Snable; R W Scott
Journal:  J Immunol       Date:  1990-01-15       Impact factor: 5.422

6.  A 25-kDa NH2-terminal fragment carries all the antibacterial activities of the human neutrophil 60-kDa bactericidal/permeability-increasing protein.

Authors:  C E Ooi; J Weiss; P Elsbach; B Frangione; B Mannion
Journal:  J Biol Chem       Date:  1987-11-05       Impact factor: 5.157

7.  Bactericidal/permeability-increasing protein and lipopolysaccharide (LPS)-binding protein. LPS binding properties and effects on LPS-mediated cell activation.

Authors:  C G Wilde; J J Seilhamer; M McGrogan; N Ashton; J L Snable; J C Lane; S R Leong; M B Thornton; K L Miller; R W Scott
Journal:  J Biol Chem       Date:  1994-07-01       Impact factor: 5.157

8.  Platelet-activating factor receptor antagonist BN 52021 in the treatment of severe sepsis: a randomized, double-blind, placebo-controlled, multicenter clinical trial. BN 52021 Sepsis Study Group.

Authors:  J F Dhainaut; A Tenaillon; Y Le Tulzo; B Schlemmer; J P Solet; M Wolff; L Holzapfel; F Zeni; D Dreyfuss; J P Mira
Journal:  Crit Care Med       Date:  1994-11       Impact factor: 7.598

9.  Bactericidal/permeability-increasing protein protects vascular endothelial cells from lipopolysaccharide-induced activation and injury.

Authors:  M Arditi; J Zhou; S H Huang; P M Luckett; M N Marra; K S Kim
Journal:  Infect Immun       Date:  1994-09       Impact factor: 3.441

10.  Efficacy and safety of monoclonal antibody to human tumor necrosis factor alpha in patients with sepsis syndrome. A randomized, controlled, double-blind, multicenter clinical trial. TNF-alpha MAb Sepsis Study Group.

Authors:  E Abraham; R Wunderink; H Silverman; T M Perl; S Nasraway; H Levy; R Bone; R P Wenzel; R Balk; R Allred
Journal:  JAMA       Date:  1995 Mar 22-29       Impact factor: 56.272
View more
  3 in total

Review 1.  A neutrophil-derived anti-infective molecule: bactericidal/permeability-increasing protein.

Authors:  O Levy
Journal:  Antimicrob Agents Chemother       Date:  2000-11       Impact factor: 5.191

2.  Therapies for sepsis. Emerging therapies for sepsis and septic shock.

Authors:  E Abraham
Journal:  West J Med       Date:  1997-03

Review 3.  Killing three birds with one BPI: Bactericidal, opsonic, and anti-inflammatory functions.

Authors:  Jomkuan Theprungsirikul; Sladjana Skopelja-Gardner; William F C Rigby
Journal:  J Transl Autoimmun       Date:  2021-05-28
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.